After 5 years still a penny stock!
IMO, GR has absolutely no intention of uplisting, period.
IMO, all smoke and mirrors.
The problem is IMO:
"We continue to repay our debt financing's in shares of common stock, enabling us to use our cash resources to fund our operations."
The problem is IMO:
"We have no therapeutic products currently available for sale and do not expect to have any therapeutic products commercially available for sale for a period of years, if at all. These factors indicate that our ability to continue research and development activities is dependent upon the ability of management to obtain additional financing as required."
The problem is IMO:
We expect that research and development expenses will increase in the foreseeable future as we add personnel, expand our pre-clinical research, continue clinical trial activities, and increase our regulatory compliance capabilities."
Umgawa>?
News 
Market Data 
Discover 
